MedTrace Logo

Effect of Exercise With and Without HMB on Body Composition and Muscle Strength in Sickle Cell Anaemia

NCT04001907 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-06-28

No results posted yet for this study

Summary

Wasting is a common and significant problem in sickle cell anaemia (SCA) that correlates with poorer clinical outcome such as frequent painful crises, acute chest syndrome and sub normal resistance to infection. Thus, improvement of nutritional status in SCA holds the potential of ameliorating the course of the disease. Elevated haemolysis and its effects are associated with hypermetabolism and have resulted in higher rates of protein breakdown and synthesis, and energy expenditure. Offering more food has not optimized nutritional status and metabolic performance in free-living patients with SCA. Moreover, appetite might be suppressed. Supplementation with β-hydroxy-β-methylbutyrate (HMB), which is produced in the body from leucine, has been shown to have inhibitory effect on protein breakdown and to promote lean tissue synthesis in humans with sarcopenia. Also, HMB has been implicated as an ergogenic tool to promote exercise performance and skeletal muscle hypertrophy. Therefore, the investigators hypothesize that in individuals with SCA, an intervention of resistance exercise with HMB supplement will have a greater enhancing effect on muscle mass and strength compared to receiving resistance exercise without HMB.

Conditions

Interventions

BEHAVIORAL

Resistance exercise

effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.

DIETARY_SUPPLEMENT

β-hydroxy-β-methylbutyrate

DIETARY_SUPPLEMENT

placebo

Sponsors & Collaborators

  • The University of The West Indies

    lead OTHER

Principal Investigators

  • Asha V Badaloo, PhD · Tropical Metabolism Research Unit, CAIHR, University of the West Indies

  • Marvin E Reid, MBBS, PhD · Tropical Metabolism Research Unit, CAIHR, University of the West Indies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-03-07
Completion
2019-11-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04001907 on ClinicalTrials.gov